[PonkenPlonken]

https://www.businesswire.com/news/home/20241117936734/en/Alnylam-Announces-Interim-Phase-1-Data-of-Nucresiran-ALN-TTRsc04-Showing-Rapid-Knockdown-of-TTR-that-is-Sustained-at-Six-Months-Following-a-Single-Dose

[TechandBio]

The next LLY will be the RNAI king!

$ALNY

[whytestocks]

Just In: $ALNY Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

In 1962, the Nobel Prize was awarded to Francis Crick and James Watson for their discoveries related to deoxyribonucleic acid (DNA), the genetic code that provides instructions to cells. Messenger ribonucleic acid (mRNA), the intermediate step between DNA and proteins, can be bound and degr...

Got this from ALNY - Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

[MinnieM]

Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19

https://investors.alnylam.com/press-release?id=24796

May 04, 2020

- Highly Potent and Broadly Cross-Reactive RNAi Therapeutic Development Candidate Selected Only Three Months After Program Initiation -

- Companies Expect to Start Human Clinical Trials at or Around Year-End 2020 –

[whytestocks]

$ALNY short squeeze article Alnylam Pharmaceuticals Inc Nasdaq Alny Short Squeeze

[whytestocks]

News: $ALNY Alnylam to Webcast Presentations at Upcoming December Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2 nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 1:15 pm ET at the Four Se...

Got this from ALNY - Alnylam to Webcast Presentations at Upcoming December Investor Conferences

[zerowinner]

Stock is going to the moon

[whytestocks]

News: $ALNY Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI(TM) (givosiran)

− Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial Certainty if Disease Prevalence is Higher Than Anticipated ...

Read the whole news ALNY - Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI(TM) (givosiran)

[whytestocks]

News: $ALNY Alnylam Announces Approval of GIVLAARI(TM) (givosiran) by the U.S. Food and Drug Administration (FDA)

− GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA Approval Received in Less Than Four Months after N...

Read the whole news ALNY - Alnylam Announces Approval of GIVLAARI(TM) (givosiran) by the U.S. Food and Drug Administration (FDA)

[whytestocks]

News: $ALNY Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

− Initial Results From ILLUMINATE-C Expected in Late 2020 – − In Phase 2 OLE, Lumasiran Treatment Resulted in 76 percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leadi...

Got this from ALNY - Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

[Glider549]

Phase 3 data, due in the 3rd quarter of 2019.

[MinnieM]

It's going a bit crazy in the after hours market.

[doughboy2]

Agree.

[MinnieM]

It will be interesting to see the following weeks prices.

[oxnous]

Who would have predicted that ALNY would get to this price without significant revenues yet?

[FooBarAndGrill]

IMO of course.

Recent Statement of Changes in Beneficial Ownership.

On November 15 2017 John Marangamore, Chief Executive Officer, in my opinion Acquired 74000 shares at $31.39 and Disposed 74000 at $126.864 for a computed amount of $9,387,951.301


W O R K S H E E T

22460 * $125.544 = 2819718.24
28399 * $126.603 = 3595398.597
07120 * $127.540 = 0908084.80
10571 * $128.484 = 1358204.364
04850 * $129.570 = 0628414.5
00600 * $130.218 = 0078130.8
------------------------------------
74000 * $126.864 = 9387951.301

Compare these computed numbers to other numbers in the most recent 10-q and draw your own conclusions.

IMO of course.

[FooBarAndGrill]

IMO of course.

Summary of recent Statement of Changes in Beneficial Ownership.

On September 20 2017 Barry E Greene, President, in my opinion Acquired 76815 shares at $31.39 and Disposed 76815 at $100 for a computed amount of $5,270,277.15

On October 2 2017 Barry E Greene, President, in my opinion Acquired 85316 shares at $21.35 and Disposed 85316 at $125 for a computed amount of $8,843,003.40

Barry E Greene, President has thus in my opinion realized a computed total gain of $14,113,280.55 from the option exercises noted above.

Compare these computed numbers to other numbers in the most recent 10-q and draw your own conclusions.

IMO of course.

[FooBarAndGrill]

About RNAi

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding protein synthesis in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, with the goal of preventing disease-causing proteins from being made.

[BottomBounce]

$ALNY Alnylam Pharmaceuticals Inc. https://www.barchart.com/story/stocks/quotes/OTIC/news/3925902/best-relative-performance-in-the-biotechnology-industry-detected-in-shares-of-coherus-bioscien-chrs-otic-tsro-imgn-alny

[FooBarAndGrill]

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 2 clinical study with cemdisiran (formerly known as ALN-CC5), a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. The trial is being conducted in patients with atypical hemolytic-uremic syndrome (aHUS) and will evaluate the effect of C5 knockdown on hematologic response and renal function, as well as safety and tolerability. The Company expects to report initial clinical proof of concept data from this trial in late 2018.

[FooBarAndGrill]

I've been following developments in RNAI for years. It's great to finally see progress in this powerful tech.

[Inoviorulez]

https://seekingalpha.com/article/4109199-alnylam-sanofi-achieve-rnai-first

[FooBarAndGrill]

In addition to new data on the Company’s ESC+ platform, Alnylam scientists and collaborators presented additional pre-clinical findings showing continued leadership in RNAi technologies and delivery. First, Alnylam scientists presented further advances toward optimizing the Company’s GalNAc-siRNA conjugate platform. These included studies to further improve the mechanistic understanding of conjugate duration of activity as well as the development of advanced ESC designs with significantly improved metabolic stability and in vivo efficacy. Further, new data on Alnylam’s Reversir™ platform were presented. Specifically, optimizations were implemented that enable rapid reversal of siRNA-mediated mRNA silencing, providing the means to fine-tune the pharmacology of GalNAc-siRNA conjugates. Finally, pre-clinical data demonstrating extra-hepatic siRNA delivery, involving Centyrins, a novel class of highly stable FN3 domain proteins, were also presented as part of a research collaboration with Janssen Research & Development, LLC. Centyrin-siRNA conjugates showed excellent cross-tumor penetration and mediated robust target knockdown in a mouse xenograft tumor model. Also, the generalizability of this approach was demonstrated in vitro using Centyrins for a number of different receptors and gene targets.

[FooBarAndGrill]

“At Alnylam, we’ve been successful in advancing our ESC GalNAc-siRNA conjugate platform with many potent and generally well tolerated investigational RNAi therapeutics in clinical development, including in Phase 3 studies. Nevertheless, we continue to strive to even further optimize our RNAi therapeutics platform to achieve improved target specificity and an even greater therapeutic index. Accordingly, we were pleased to share these new pre-clinical results at this year's OTS meeting, highlighting our ESC+ GalNAc conjugate platform,” said Kevin Fitzgerald, Ph.D., Senior Vice President, Research at Alnylam. “Our goal is to employ the ESC+ chemistry in all future development candidates, beginning with ALN-AAT02, which we plan to advance into clinical development in 2018. We believe that by implementing platform improvements that preemptively address potential off-target effects we can further enhance the therapeutic index of our investigational RNAi therapeutics for all future programs in our pipeline.”

[FooBarAndGrill]

ESC+ GalNAc conjugates utilize advanced design features to further improve specificity, including a glycol nucleic acid (GNA) modification in the antisense seed region of the siRNA, while maintaining potency and durability. The data presented at OTS indicated that incorporation of GNA destabilizes seed-driven pairing with partially complementary transcripts, thus greatly reducing potential off-target effects while maintaining on-target pairing and activity. Additionally, it was shown that GNA modifications confer enhanced specificity and a greater-than 6-fold improvement in therapeutic index as observed in pre-clinical studies in rodents. The ESC+ design is now being applied to all of Alnylam’s pre-clinical programs and has shown successful translation of potency from rodents to non-human primates. Alnylam intends to employ its ESC+ siRNA-conjugate platform in all future development programs.

[FooBarAndGrill]

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its next generation “Enhanced Stabilization Chemistry Plus” (ESC+) GalNAc-siRNA conjugate platform at the 13th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held September 24 – 27, 2017 in Bordeaux, France.

[FooBarAndGrill]

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares jumped more than 40% on Wednesday after the pharma company, together with Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic designed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints. "We are very proud to report the first ever positive Phase 3 results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines. This moment is the culmination of a 15-year journey of tireless work by countless contributors who have overcome enormous scientific and business challenges to make RNAi therapeutics a reality," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.

[NewTrader93]

I am a finance graduate and have always been interested in trading but have never truly started researching until now. after looking at what has happened with this company and its stock price. such a spike would potentially lead to just as dramatic a drop in price, thus giving way to a great opportunity to short which you have stated correct?

[Bernstein]

FANTASTIC SHORT OPP TODAY...

$10 BILLION UNPROFITABLE BUBBLE FRAUD WHICH BURNING $120+ MILLION A QUARTER AN HAVE $200 MILLION DEBT = BRUTAL PONZI SCEHEME FRAUD ONGOING HERE TO ATTRACT NEWBIES SO THE CRIMINAL BANKSTERS AND BOARD MEMEBRS CAN UNLOAD THEIR TRASH = NEXT MEGA SCAM LIKE VALEANT VRX = FAIR VALUE $10 AT BEST

[Inoviorulez]

https://seekingalpha.com/article/4101274-alnylam-q3-catalysts-play

[Inoviorulez]

https://seekingalpha.com/article/4086761-alnylam-sanofi-produce-monster-alternative-hemophilia-market

[stocktrademan]

ALNY buy option 71.49

buy 16 JUN 17 75 call for 2.40









normal chart




log chart

[PennyStockC]

Back over 40/share by Tuesday.

Anyone ready?!

[rivervalley]

Liking it putting in a new high since earlier. Keep rolling on up ALNY.

[PennyStockC]

Back to over 38 we go today alone.

Weeeee

[rivervalley]

So far hod 36.07, keep it rolling :)

[rivervalley]

Picked up a starter in pm.

[PennyStockC]

After hours news prompting investigation... Ffs,
I'm flipping hard. GAP UP in am???

[ClarkKant]

Buyers stepping up now $35.90 after the two hour short pullback. If they cover tomorrow....easy $40+

[ClarkKant]

Shorts are in control right now $36.70. Looks like it is heading for a new LOD unless some covering takes place before EOD.

[conix]

ALNY? Bouncer?